MeSH D049970 - graves ophthalmopathy
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Horizon Therapeutics Public | Teprotumumab | Tepezza | 2020-01-21 | $1,835.291 M | Q3/22-Q2/23 |
Clinical Trials
Historical Success Rate
Phase 1
100%6/6
Phase 2
78%14/18
Phase 3
52%11/21
Approved: 2Overall Success rate: 41%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use